CNH to announce 2025 Q2 financial results on August 1
Basildon, July 17, 2025
CNH (NYSE: CNH) will release its financial results for the Second Quarter of 2025 on Friday, August 1, 2025. A live listen-only webcast of the financial results conference call will begin at 9:00 a.m. ET on the same day. It will be accessible here: bit.ly/CNH_Q2_2025
For those unable to participate in the live session, a replay will remain archived in the Investor Relations section of the corporate website (www.cnh.com) for 12 months.
Those interested in participating in the Q&A session should connect via telephone at least 10 minutes prior to the start of the event.
Dial-in numbers:
U.S. Toll-Free: +1 (800) 715 9871
U.S. Local: +1 (646) 307 1963
International Local: registrations.events/directory/international/itfs.html
Conference ID: 5427559
Conference name: CNH
CNH Industrial (NYSE: CNH) is a world-class equipment, technology and services company. Driven by its purpose of Breaking New Ground, which centers on Innovation, Sustainability and Productivity, the Company provides the strategic direction, R&D capabilities, and investments that enable the success of its global and regional Brands. Globally, Case IH and New Holland supply 360° agriculture applications from machines to implements and the digital technologies that enhance them; and CASE and New Holland Construction Equipment deliver a full lineup of construction products that make the industry more productive. The Company's regionally focused Brands include: STEYR, for agricultural tractors; Raven, a leader in digital agriculture, precision technology and the development of autonomous systems; Hemisphere, a leading designer and manufacturer of high-precision satellite-based positioning, and heading technologies; Flexi-Coil, specializing in tillage and seeding systems; Miller, manufacturing application equipment; and Eurocomach, producing a wide range of mini and midi excavators for the construction sector, including electric solutions.
Across a history spanning over two centuries, CNH has always been a pioneer in its sectors and continues to passionately innovate and drive customer efficiency and success. As a truly global company, CNH's 35,000+ employees form part of a diverse and inclusive workplace, focused on empowering customers to grow, and build, a better world.
For more information and the latest financial and sustainability reports visit: cnh.com
For news from CNH and its Brands visit: media.cnh.com
Contacts:
Media Relations
Email: mediarelations@cnh.com
Investor Relations
Email: investor.relations@cnh.com
Attachment
20250717_PR_CNH_Q2_Announcement
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
22 minutes ago
- Globe and Mail
agilon health, inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights
The DJS Law Group announces that it is investigating claims on behalf of investors of agilon health, inc. ('Agilon' or 'the Company') (NYSE: AGL) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. Agilon announced on August 4, 2025, that President, CEO, and Board Director Steven Sell stepped down from his positions. The Company added, 'In a separate press release, the Company today also issued its second quarter 2025 earnings results. As part of that announcement, and in conjunction with this leadership transition, the Company is withdrawing its previous full year 2025 earnings guidance.' Based on this news, shares of Agilon fell more than 27% in after hours trading following the Company's release. If you are a shareholder who suffered a loss, contact us to participate. WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Globe and Mail
2 hours ago
- Globe and Mail
CVRx (CVRX) Q2 Revenue Jumps 15%
Key Points Revenue (GAAP) rose 15% to $13.6 million, surpassing both company expectations and analyst estimates. Net loss narrowed on a per-share basis to $(0.57) (GAAP), primarily due to a higher share count despite a slight increase in overall losses. These 10 stocks could mint the next wave of millionaires › CVRx (NASDAQ:CVRX), a medical device innovator focused on heart failure therapy, released its second quarter 2025 earnings on August 4, 2025. The most important news was a Revenue (GAAP) increased to $13.6 million, up 15% year-over-year and above analyst expectations of $13.29 million (GAAP). The company also reported a net loss of $14.7 million, or $(0.57) per share (GAAP). While that loss widened slightly, the per-share figure (GAAP) improved due to an increased share count. The quarter reflected strong commercial progress for its Barostim neuromodulation device despite heavy investment in sales and marketing. Results slightly exceeded internal and external expectations, and management narrowed its revenue guidance to a range of $55.0 million to $57.0 million. Metric Q2 2025 Q2 2025 Estimate Q2 2024 Y/Y Change EPS (GAAP) $(0.57) $(0.52) $(0.65) 12.3% Revenue (GAAP) $13.6 million $13.29 million $11.8 million 15.1% Gross Profit $11.5 million N/A N/A Gross Margin 84% 84% 0% Net Loss $14.7 million $14.0 million -5.0% Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. About CVRx and Its Core Business CVRx (NASDAQ:CVRX) specializes in developing implantable medical devices for treating heart failure. Its leading product, Barostim, is a neuromodulation device—meaning it delivers targeted electrical pulses to nerves in the carotid artery to improve function of the autonomic nervous system. This system regulates key bodily functions, including blood pressure and heart rate. Barostim is designed to treat patients with heart failure with reduced ejection fraction (HFrEF), providing an option that avoids direct implantation in the heart. The company's commercial priorities are building deep adoption in centers with strong heart failure programs and expanding reimbursement pathways to improve access. Solid clinical evidence and reliable regulatory support have been the company's main success factors, along with educating physicians and patients on Barostim's benefits. Quarter Highlights and Key Developments During the period, total revenue (GAAP) reached $13.6 million, outpacing both the company's guides and Wall Street expectations by over 2%. U.S. heart failure revenue remained the largest contributor, climbing to $12.1 million, with units up to 387 from 339 in the prior year. U.S. sales overall were $12.2 million, also up 15% (GAAP). Across the Atlantic, European revenue grew 19% to $1.3 million (GAAP), but the number of European implant units declined from 63 to 61, signaling some softness in procedural volume despite improved pricing or product mix. Active implanting centers in the U.S. grew to 240, reflecting 13 new centers added in the U.S. during the quarter. U.S. sales territories also grew to 47, up from 45, while European territories held steady at five. U.S. revenue accounted for approximately 89.8% of total sales (GAAP), indicating the company's primary growth engine remains domestic. The company attributes revenue gains to both new account additions and greater utilization per center, while the slightly lower European volumes point to variability in adoption across geographies. Gross profit (GAAP) grew 16% from the prior year, maintaining a gross margin of 84%. On the expense side, research and development (R&D) spending declined 11% to $2.5 million, reflecting lower compensation as resources shifted toward commercial growth. Selling, general, and administrative (SG&A) costs (GAAP) increased 11% to $23.4 million, driven mainly by higher employee compensation, travel, and non-cash stock-based grants, with some relief from lower advertising costs. The higher SG&A, while outpaced by revenue growth, resulted in operating and net losses that remain substantial—operating loss (GAAP) at $14.4 million and net loss (GAAP) at $14.7 million. Multiple reimbursement milestones provided stability for Barostim's future. The Centers for Medicare & Medicaid Services (CMS) proposed to retain Barostim as a covered outpatient procedure at the $45,000 payment level, removing some uncertainty for hospitals and ensuring continued access. In addition, CMS proposed favorable physician payment levels of about $550 for new procedure coding effective in 2026. On the clinical front, highlighted real-world data presented at major cardiology conferences showed large reductions in heart failure hospital visits—down 85% for heart failure, 84% for cardiovascular causes, and 86% for all causes—after Barostim implantation, based on comparisons of hospital visits for 306 Barostim patients in the 12 months prior to implant and an average of almost two years post-implant. These real-world results have been well received by physicians and payers, which it views as an important driver of payer support and future uptake. Furthermore, the company is preparing a large pragmatic randomized controlled trial (RCT), potentially enrolling up to 2,000 patients, to further establish Barostim's efficacy, as discussed in recent management commentary. Although the timing and costs of that effort depend on regulatory approval and payer support, management sees it as a long-term enabler of broader use. The company finished the quarter with $95.0 million in cash and cash equivalents, down from $105.9 million at year end 2024. Net cash used for operations and investing was $8.0 million, showing some improvement from $10.2 million a year ago, but still indicating ongoing cash burn. Long-term debt remained steady at $49.4 million. Looking Ahead: Guidance and Watch Items For fiscal 2025, management narrowed its revenue guidance to $55.0–$57.0 million, tightening the prior range and signaling increased confidence from better visibility into commercial results. The company expects gross margin to remain high at 83–84%. Operating expenses are now projected at $96.0–$98.0 million, a slight increase at the midpoint, reflecting ongoing investments in sales and account growth. Revenue is expected in the range of $13.7–$14.7 million for the next quarter, suggesting continued double-digit revenue growth ahead, as evidenced by a 15% year-over-year increase. Areas to watch in the coming quarters include progress in adding new implanting centers, the effectiveness and productivity of the enlarged sales force, and movement toward scaling revenues faster than expenses. Investors will also monitor any shift in European procedure volumes, cash usage trends, and the company's progress on the planned large RCT, as this trial could both validate Barostim's utility and expand the addressable market if successful. CVRX does not currently pay a dividend. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,019%* — a market-crushing outperformance compared to 178% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 4, 2025
Globe and Mail
5 hours ago
- Globe and Mail
Palomar (PLMR) Q2 Revenue Jumps 55%
Key Points Non-GAAP EPS reached $1.76 in Q2 2025, beating non-GAAP analyst estimates and This figure represents a 40.8% increase compared to Q2 2024. GAAP revenue totaled $203.3 million in Q2 2025, This was up 55.1% year over year. Palomar raised its full-year adjusted net income guidance for 2025 and continued to diversify beyond its core earthquake insurance segment. These 10 stocks could mint the next wave of millionaires › Palomar (NASDAQ:PLMR), a specialty property insurance provider known for its focus on niche markets such as earthquake and specialty lines, announced its Q2 2025 results on August 4, 2025. The most important headline: Palomar delivered better-than-expected non-GAAP earnings per share and raised its outlook for adjusted net income for 2025. Non-GAAP earnings per share came in at $1.76, ahead of the $1.67 non-GAAP analyst estimate, while GAAP revenue was reported as $203.3 million. Net earned premiums, a core insurance metric, climbed 47.2% year-over-year (GAAP). Overall, the period was marked by solid organic growth across key business lines, increases in profitability, and tangible progress on Palomar's diversification initiatives. Metric Q2 2025 Q2 2025 Estimate Q2 2024 Y/Y Change EPS (Non-GAAP) $1.76 $1.67 $1.25 40.8 % Revenue (GAAP) $203.3 million N/A $131.1 million 55.1 % Net Earned Premiums $180.0 million $122.3 million 47.2 % Adjusted Combined Ratio 73.1 % 73.1 % 0.0 % Annualized Adjusted Return on Equity 23.7 % 24.7 % (1.0) pp Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Palomar's Business and Growth Focus Palomar's core business centers on specialty property and casualty insurance for underserved risk categories. It holds a prominent position in earthquake insurance in California, is growing rapidly in casualty, with gross written premium for casualty increasing 113% year-over-year, and also serves markets like inland marine, fronting, and crop insurance. Its competitive edge comes from using advanced technology platforms and proprietary analytics for underwriting and pricing, allowing for speed and flexibility. In recent years, Palomar has prioritized diversification. It is broadening its insurance offerings outside earthquake coverage, focusing on product expansion, geographic reach, and customer mix. These moves aim to reduce its reliance on any single risk type or region. Key success factors include disciplined risk management, strong reinsurance programs, and investments in operational technology. Quarter in Detail: Revenue Growth, Segment Trends, and Profitability Drivers Palomar saw a notable increase in business activity. Net earned premiums (GAAP) increased from $122.3 million in Q2 2024 to $180.0 million, reflecting expansion across product lines. Growth in premiums written was strongest in the casualty segment, which surged 118.8% to $128.2 million and The casualty segment now composes over a quarter of total gross written premium. Inland marine and property lines gross written premiums grew 28.4%. Crop insurance posted impressive gains, with gross written premium rising from $2.2 million to $39.5 million year over year. Conversely, the fronting segment, previously a larger contributor, declined 36.5% as expected due to the wind-down of a major partnership. The diversification strategy was evident in the quarterly mix: earthquake made up 29.8% of gross written premiums (down from 35.1% in Q2 2024), while no single line exceeded that share. Geographically, California exposure was 33.0% of gross written premium, further highlighting Palomar's broader portfolio. This balance limits concentration risk and reflects a shift toward markets with higher growth potential. Key profitability metrics also improved. The adjusted combined ratio (non-GAAP), which measures claims and expenses as a percentage of premiums earned, remained stable at 73.1%. The combined ratio excluding catastrophe losses ticked up, and upfront expense recognition related to crop business expansion. Loss ratios, which show claims costs compared to premiums, rose modestly from 24.9% in Q2 2024 to 25.7%, while the catastrophe loss ratio (non-GAAP) dropped to zero, signaling an absence of major insured events this period. The expense ratio (GAAP) improved, falling to 53.1% from 54.2% compared to Q2 2024. Earthquake insurance, Palomar's original specialty, recorded slower but steady growth, with management expecting mid- to high-teens gross written premium growth for FY2025. Thanks to investments in new talent and acquisitions like Advanced AgProtection. Notably, the fronting business is in runoff and becoming less significant for the company's outlook. On the finance side, net investment income rose 68.0% year over year, benefiting from higher yields and a bigger asset base, while annualized adjusted return on equity (non-GAAP) was 23.7%. Strategic Initiatives and Risk Management Execution During the period, Palomar made progress on several strategic initiatives. Specialty insurance markets like earthquake remain core to its identity, but expansion in casualty, crop, and inland marine has reshaped its revenue balance. The acquisition of Advanced AgProtection expanded the crop business's geographic reach and distribution footprint. Meanwhile, the planned runoff of the fronting segment, particularly following the termination of larger partnerships, continued as forecast and should have less impact after the next quarter. The company also executed a successful renewal of its reinsurance program at an adjusted rate decrease of approximately 10% year-over-year. Reinsurance is a form of insurance for insurers, letting Palomar limit its exposure to large, unpredictable events like natural disasters. The structure of its catastrophe bond placements and reinsurance treaties has further reduced volatility, as evidenced by the minimal catastrophe losses this quarter. Investment in technology and analytics was again highlighted, supporting automation and operational scale. These efforts allow for more targeted underwriting in specialty lines and maintain Palomar's competitive position, though the company is incurring additional costs as it builds out new lines, especially crop. The company does not currently pay a dividend. Looking Ahead: Outlook and Watch Points Management raised its full-year adjusted net income guidance to a range of $198–208 million (non-GAAP) for 2025, up from the prior estimate of $186–200 million (adjusted net income). This new outlook factors in a likely $8–12 million in catastrophe-related losses for the remainder of the year, as well as the expected seasonal effects from crop insurance operations. Overall, the company expects the combined ratio to be in the mid-to-upper 70% range. Investors should monitor several evolving trends and risks. These include sustained growth in casualty and crop gross written premiums, ongoing reduction in the fronting segment, expense levels tied to scaling new lines, the attritional loss ratio as business mix changes, and potential shifts in reinsurance market conditions. Analysts will look to see—especially as the company adapts to changing competitive pressures. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,019%* — a market-crushing outperformance compared to 178% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 4, 2025
